Антифосфолипидный синдром - Насонов Е.Л.
ISBN 5-98216-010-5
Скачать (прямая ссылка):
63. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthiritis and rheumatoid arthritis: systemic review of randomized controlled trials. BMJ 2002; 325: 1—8.
64. Baker CS, Hall RJ, Evans TJ et al. Cyclooxygenase 2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalized with inducible nitric oxide synthase and nitrotyrosine particularly macrophages. Atheroscler Thromb Vasc Biol 1999; 19: 646—655.
65. Schonbeck U, Sukhova GK, Graber P, et al. Augmented expression of cyclooxigenase-2 in human atherosclerotic lesions. Am J Pathol 1999; 155: 1281—1291.
66. Burleigh ME, Babaev VR, Oates JA, et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor deficiency mice. Circulation 2002; 105: 1816—1823.
67. Cippilone F, Prontera C, Pini B, et al. Overexpression of functionally coupled cyclooxy-genase E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E2-depen-dent plaque instability. Circulation 2001; 104: 921—930.
68. Belton O, Byrne D, Kearney D, et al. Cyclo-oxygenase-1 and — 2 dependent prostacyclin for-
SHS-OOO4.qxd 21.11.2006 16:56 Page 4226"
26
Насонов Е.Л. Антифосфолипидный синдром.
mation in patients with atherosclerosis. Circulation 2000; 102: 840—845.
69. Saito T, Rodger IW, Hu E, et al. Inhibition of cyclooxygenase-2 improves cardiac function in myocardial infarction. Biochem Biophys Res Commun 2000; 273: 772—775.
70. Chenevard R, Hurlimann D, Bechir M, et al. Selective COX-2 inhibition improves endothe-lial function in coronary artery disease. Circulation 2003; 107.
71. Heindt H, Becker BF. Aspirin, but not the more selective cyclooxygenase (COX)-2 inhibitors meloxicam and SC 58125, aggravates posis-chemic cardiac dysfunction, independent of COX function. Naunyn-Schmiedeberg's Arch Pharma-col.,2001; 363: 233—240.
72. Altman R, Luciardi HL, Muntaner J, et al. Efficacy of assessment of meloxicam. A preferential COX-2 inhibitor in acute coronary syndromes without ST-segment elevation, the NUT-2 pilot study. Circulation 2002; 106: 191—195.
73. Howard PA. Aspirin resistance Ann Pharmacotherapy 2002; 36: 1620—1624.
74. Gum PA, Kottke-Marchant K, Poggio Ed, et al. Profile and prevalence of aspirin resistence in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230—234.
75. Weber AA, Zimmermann KC, Meyer-Kirchrath J, Schor K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistence. Lancet 1999; 353: 900.
76. Rocca B, Secchiero P, Giabattoni G, et al. Cycloxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. PNAS 2002; 99: 7634—7639.
77. Halushka MK, Halushka PV. Why are some individuals resistant to the cardioproyective effects of aspirin. Could it be thromboxane A2. Circulation 2002; 105: 1620—1622.
78. Eikelboom JW, Hirch J, WeitJi, et al. Aspirin-resistant thromboxane biosynthesis and risk of myocardial infarction, stroke. Or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650— 1655.
79. Ferro D, Basill S, Roccaforte S, et al. Determinants of enhanced thromboxane biosynthesis in patients with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 2689—2697.
80. Azar RR, Rinfret S, Theroux P, et al. A randomized placebo-controlled trial to asses the efficacy of antiinflammatory therapy with methyl-prednisolone in unstable angina. (MUNA trial). Eur Heart J 2000; 21: 2026—2032.
81. Versaci F, Gaspardone A, Tomai F, et al. Immunosupressive therapy for the prevention of restenosis after coronary artery stent implantation (IMPRESS Study). J Am Coll Cardiol 2002; 40: 1935—1942.
82. Cippolone F, Ganci A, Greco A, et al. Modulation of aspirin-insensitive eicosanoid biosynthesis by 6-methylprednisolone in unstable angina. Circulation 2003; 10&: 55.
83. Weyand CM, Kaiser M, Yang H, et al. Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthritis Rheum 2002; 46: 457—466.
84. Nesher G, Mates M, Barkum Y, et al. Low dose aspirin and prevention of stroke and visual loss in giant cell arteritis. ACR 6 Annual Scientific Meeting, Oktober 24—29, 2002; 402 (abst).
Противовоспалительные эффекты ингибиторов АПФ и антагонистов рецепторов ан-гиотензина II типа I
1. Linz W, Wohlfart P, Schoelkens Ba, et al. Interactions among ACE, kinins and NO. Cardiovasc Res 1999; 43: 549—561.
2. Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al. Expression of angiotensin II and interleukin 6 in human coonary atherosclerotic plaques: potential implications for inflammation and plaque stability. Circulation 2000; 101: 1372— 1378.
3. Kranzhofer R, Scmidt J, Pfeifer CAH, et al. Angiotensin induced inflammatory activation of human vascular smooth muscle cells. Arteriol Thromb Vasc Biol 1999; 19: 1623—1629.
4. Bunte C, Witte J, Hoeper K, Schieffer B. Contrasting anti-atherosclerotic effects of AT1-antagonism and ACE inhibition in patients with coronary artery disease: potential impact on plaque passivation. Circulation 2002; 19: II— 337. (abst 1684).
